Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Osimertinib Mesylate Tablets in the Treatment of Recurrent and Metastatic Non- Small Cell Lung Cancer

NCT05020769 is registered in ClinicalTrials.gov with Sichuan Baili Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05020769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05020769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Osimertinib Mesylate Tablets in the Treatment of Recurrent and Metastatic Non- Small Cell Lung Cancer
Lead sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
January 6, 2022
Completion date
December 31, 2025
Enrollment
14 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer